POTOMAC, Maryland, April 28, 2026

IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA clinical trial for IGC-AD1, an investigational therapy for agitation in Alzheimer’s dementia, approaches final enrollment. With approximately 80% patient enrollment completed, the company is accelerating awareness initiatives through participation in the caregiver-focused podcast Autumn Is Here, reinforcing the importance of early symptom recognition and stronger patient participation in Alzheimer’s clinical research.

Supporting Alzheimer’s Clinical Progress Through Awareness

As the CALMA Phase 2 trial moves toward enrollment completion, IGC Pharma is focusing on caregiver education as a critical component of both patient support and clinical trial success. Agitation is one of the most challenging and often under-recognized symptoms of Alzheimer’s disease, significantly affecting both patients and caregivers.

Through the podcast discussion, IGC Pharma experts highlighted how agitation presents differently from other behavioral symptoms and why early recognition is essential for timely intervention and improved care outcomes. The company believes that increasing public understanding of agitation can help families seek appropriate support sooner while also improving participation in ongoing therapeutic studies.

Connecting Research With the Caregiver Community

Advertisement

cGxPJobs Banner

The featured episode included Margarita Venegas, Psychometric Training Manager, and Barbara Forero, Clinical Neuropsychologist and Recruitment Coordinator at IGC Pharma, alongside podcast host Francine Crawford, who brings a personal caregiving perspective to the conversation.

Their discussion focused on the emotional and clinical burden of agitation in Alzheimer’s dementia and the importance of caregiver involvement in research. According to CEO Ram Mukunda, engaging directly with caregivers helps bridge the gap between clinical development and real-world patient needs, ensuring that treatment innovation remains closely aligned with the daily challenges faced by families managing Alzheimer’s disease.

CALMA Trial Momentum and Future Pipeline Growth

IGC Pharma’s lead asset, IGC-AD1, is currently being evaluated in the randomized, double-blind, placebo-controlled Phase 2 CALMA trial, which aims to address agitation associated with Alzheimer’s dementia — an area with significant unmet medical need. The company has recently reached approximately 80% enrollment and is advancing toward final completion and future data readout.

Beyond CALMA, IGC Pharma is leveraging artificial intelligence-driven drug discovery across its broader pipeline, including TGR-63, which targets amyloid plaques, and additional early-stage neurodegeneration and metabolic disease programs.

By combining AI-powered therapeutic development, strong caregiver engagement, and targeted Alzheimer’s research, IGC Pharma is positioning itself as an emerging leader in neurodegenerative disease innovation. As the CALMA trial advances, the company’s patient-centered outreach strategy may play a vital role in accelerating enrollment, improving disease awareness, and ultimately bringing new treatment options to patients living with Alzheimer’s agitation.

Source: IGC Pharma press release